SCM
AXSM icon

Soleus Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Soleus Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,000
Closed -$209K – 92
2025
Q2 		$209K Sell
2,000
-15,000
-88% -$1.59M 0.01% 94
2025
Q1 		$1.98M Buy
+17,000
New +$1.94M 0.14% 62
2023
Q4 		– Sell
-237,500
Closed -$16.6M – 78
2023
Q3 		$16.6M Buy
237,500
+212,600
+854% +$15.9M 1.53% 22
2023
Q2 		$1.79M Buy
24,900
+4,200
+20% +$310K 0.2% 76
2023
Q1 		$1.28M Sell
20,700
-29,300
-59% -$1.92M 0.13% 70
2022
Q4 		$3.86M Buy
+50,000
New +$2.99M 0.55% 44

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Soleus Capital Management's AXSM Position: Q3 2025 in Review

Soleus Capital Management sold out of Axsome Therapeutics (AXSM) in Q3 2025, closing a stake of 2,000 shares — an estimated $209K sold.

Soleus Capital Management first reported a position in AXSM in Q4 2022 and held it in 6 quarters. The position peaked at $16.6M in Q3 2023. 355 funds tracked by Wall St. Rank hold AXSM as of Q3 2025.

  • Soleus Capital Management reported no remaining Axsome Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Soleus Capital Management sold 2,000 Axsome Therapeutics shares in Q3 2025, an estimated $209K.
  • Soleus Capital Management first reported a position in Axsome Therapeutics in Q4 2022 and held it in 6 quarters.
  • Soleus Capital Management's Axsome Therapeutics position peaked at $16.6M in Q3 2023.
  • 355 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2025.

Based on Soleus Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.